Horizon Pharma Inc. (HZNP) Trading 2.2% Higher
Horizon Pharma Inc. (NASDAQ:HZNP) shares traded up 2.2% during mid-day trading on Thursday . The stock traded as high as $18.15 and last traded at $17.89, with a volume of 2,109,744 shares. The stock had previously closed at $17.51.
Several research analysts have issued reports on the company. Stifel Nicolaus reiterated a “buy” rating and set a $45.00 price objective on shares of Horizon Pharma in a research note on Wednesday. BMO Capital Markets started coverage on Horizon Pharma in a report on Tuesday, June 28th. They set an “outperform” rating and a $29.00 target price on the stock. Vetr upgraded Horizon Pharma from a “buy” rating to a “strong-buy” rating and set a $21.00 target price on the stock in a report on Monday, June 13th. Goldman Sachs Group Inc. started coverage on Horizon Pharma in a report on Monday, June 6th. They set a “buy” rating and a $24.00 target price on the stock. Finally, Citigroup Inc. started coverage on Horizon Pharma in a report on Wednesday, June 1st. They set a “neutral” rating on the stock. Two research analysts have rated the stock with a sell rating, two have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $29.38.
The company has a market cap of $3.00 billion and a PE ratio of 242.99. The firm’s 50-day moving average is $17.06 and its 200-day moving average is $17.11.
Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported $0.34 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.30 by $0.04. The company earned $204.70 million during the quarter, compared to analyst estimates of $197.73 million. During the same period in the prior year, the firm earned $0.18 earnings per share. Horizon Pharma’s revenue was up 80.9% on a year-over-year basis. On average, equities research analysts expect that Horizon Pharma Inc. will post $2.35 EPS for the current fiscal year.
In other news, Director Virinder Nohria sold 25,000 shares of the business’s stock in a transaction on Wednesday, June 15th. The stock was sold at an average price of $17.69, for a total transaction of $442,250.00. Following the completion of the transaction, the director now owns 189,836 shares of the company’s stock, valued at approximately $3,358,198.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Several institutional investors have bought and sold shares of HZNP. Teacher Retirement System of Texas boosted its position in Horizon Pharma by 87.4% in the fourth quarter. Teacher Retirement System of Texas now owns 2,136,961 shares of the biopharmaceutical company’s stock worth $46,308,000 after buying an additional 996,761 shares during the period. Hodges Capital Management Inc. boosted its position in Horizon Pharma by 4.1% in the fourth quarter. Hodges Capital Management Inc. now owns 1,571,794 shares of the biopharmaceutical company’s stock worth $34,061,000 after buying an additional 61,454 shares during the period. Tekla Capital Management LLC boosted its position in Horizon Pharma by 130.2% in the fourth quarter. Tekla Capital Management LLC now owns 749,900 shares of the biopharmaceutical company’s stock worth $16,250,000 after buying an additional 424,100 shares during the period. CAM Group Holding A S acquired a new position in Horizon Pharma during the fourth quarter worth approximately $14,335,000. Finally, Dimensional Fund Advisors LP boosted its position in Horizon Pharma by 104.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 557,772 shares of the biopharmaceutical company’s stock worth $12,089,000 after buying an additional 284,359 shares during the period.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.